Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.

BACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D conc...

Full description

Bibliographic Details
Main Authors: Sharon L McDonnell, Carole A Baggerly, Christine B French, Leo L Baggerly, Cedric F Garland, Edward D Gorham, Bruce W Hollis, Donald L Trump, Joan M Lappe
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6003691?pdf=render
id doaj-7fb283cd81f2415794b8294c03ecd9a5
record_format Article
spelling doaj-7fb283cd81f2415794b8294c03ecd9a52020-11-25T01:19:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019926510.1371/journal.pone.0199265Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.Sharon L McDonnellCarole A BaggerlyChristine B FrenchLeo L BaggerlyCedric F GarlandEdward D GorhamBruce W HollisDonald L TrumpJoan M LappeBACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older. METHODS:Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements. RESULTS:Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin. CONCLUSIONS:Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective.http://europepmc.org/articles/PMC6003691?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sharon L McDonnell
Carole A Baggerly
Christine B French
Leo L Baggerly
Cedric F Garland
Edward D Gorham
Bruce W Hollis
Donald L Trump
Joan M Lappe
spellingShingle Sharon L McDonnell
Carole A Baggerly
Christine B French
Leo L Baggerly
Cedric F Garland
Edward D Gorham
Bruce W Hollis
Donald L Trump
Joan M Lappe
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
PLoS ONE
author_facet Sharon L McDonnell
Carole A Baggerly
Christine B French
Leo L Baggerly
Cedric F Garland
Edward D Gorham
Bruce W Hollis
Donald L Trump
Joan M Lappe
author_sort Sharon L McDonnell
title Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
title_short Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
title_full Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
title_fullStr Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
title_full_unstemmed Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
title_sort breast cancer risk markedly lower with serum 25-hydroxyvitamin d concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/l): pooled analysis of two randomized trials and a prospective cohort.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description BACKGROUND:While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml. OBJECTIVE:To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older. METHODS:Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements. RESULTS:Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin. CONCLUSIONS:Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective.
url http://europepmc.org/articles/PMC6003691?pdf=render
work_keys_str_mv AT sharonlmcdonnell breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT caroleabaggerly breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT christinebfrench breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT leolbaggerly breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT cedricfgarland breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT edwarddgorham breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT brucewhollis breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT donaldltrump breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
AT joanmlappe breastcancerriskmarkedlylowerwithserum25hydroxyvitamindconcentrations60vs20ngml150vs50nmollpooledanalysisoftworandomizedtrialsandaprospectivecohort
_version_ 1725137054094852096